Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis
US6306400A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jul 28, 1999 |
| Grant date | Oct 23, 2001 |
| Priority date | — |
| Expiry date | Jul 28, 2019 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/816
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The avian recombinant live vaccine comprises, as vector, an ILTV virus comprising and expressing at least one heterologous nucleotide sequence, this nucleotide sequence being inserted into the insertion locus formed by the intergenic region situated between the stop codons of the ORF D and ORF E of ILTV and which, in a specific ILTV strain, is defined between nucleotides 3873 and 4260 in SEQ ID No:1. The heterologous nucleotide sequence may be under the control of a strong eukaryotic promoter, such as the CMV-IE promoter, and may be derived from the Newcastle disease virus, Marek's disease virus, the infectious bursal disease virus, the infectious bronchitis virus, the chicken anaemia virus and the chicken pneumovirosis virus. Multivalent vaccine formula comprising at least two live vaccines according to the invention. ILTV virus thus recombined.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.